Results 241 to 250 of about 503,802 (298)

Rationalizing the Development of Live Attenuated Virus Vaccines [PDF]

open access: yesNature Biotechnology, 2010
The design of vaccines against viral disease has evolved considerably over the past 50 years. Live attenuated viruses (LAVs)-those created by passaging a virus in cultured cells-have proven to be an effective means for preventing many viral diseases ...
Raul Andino   +2 more
exaly   +2 more sources

Live Attenuated Influenza Vaccine

2014
Cold-adapted Ann Arbor based live attenuated influenza vaccine (LAIV) has been available in the USA since 2003. The vaccine is efficacious against influenza infection. Features of LAIV include: easy administration suitable for mass immunization, cross-reactivity to drifted strains for broader coverage, and establishment of herd immunity for control of ...
Hong, Jin, Kanta, Subbarao
openaire   +2 more sources

LIVE ATTENUATED VARICELLA VACCINE

Annual Review of Microbiology, 1996
Varicella-zoster virus (VZV) is a ubiquitous human pathogen that causes varicella, commonly called chicken pox; establishes latency; and reactivates as herpes zoster, referred to as shingles. A live attenuated varicella vaccine, derived from the Oka strain of VZV has clinical efficacy for the prevention of varicella.
A M, Arvin, A A, Gershon
openaire   +2 more sources

Live Attenuated Vaccine Vectors

International Journal of Technology Assessment in Health Care, 1994
AbstractSeveral different live attenuated vaccine vectors currently are under development. These vaccines are composed of living viruses or bacteria that are innocuous to the host but can replicate in host tissues and induce immune responses. The genes encoding foreign antigens can be inserted into these vectors to produce multivalent vaccines that ...
openaire   +2 more sources

Attenuation Methods for Live Vaccines

2020
Vaccination was developed by Edward Jenner in 1796. Since then, vaccination and vaccine development research has been a hotspot of research in the scientific community. Various ways of vaccine development are successfully employed in mass production of vaccines. One of the most successful ways to generate vaccines is the method of virulence attenuation
Dipasree, Hajra   +2 more
openaire   +2 more sources

Vaccination with Attenuated Measles-Virus Vaccine

American Journal of Diseases of Children, 1962
The immunological efficacy and the absence of communicability of live attenuated measles-virus vaccine in children has been described by Katz and Enders 1 and by others 2-10 Since immunity to natural measles infection shortly after vaccination has also been reported, 3,4 the final acceptance of this vaccine for routine pediatric immunization will ...
P, HALONEN   +6 more
openaire   +2 more sources

Live Attenuated Influenza Vaccine - A review

Journal of preventive medicine and hygiene, 2011
Owing to the variability of influenza viruses, vaccine composition needs to be up-dated annually. As many variables can influence their efficacy, vaccines are still considered ?sub-optimal?. Many studies have been carried out in recent years to improve vaccines.
GASPARINI, ROBERTO   +3 more
openaire   +3 more sources

Live attenuated influenza vaccine

2008
The development of the live, attenuated influenza vaccine (LAIV), based on the cold-adapted (ca), attenuated ca A/Ann Arbor/6/60 and ca B/Ann Arbor/1/66 backbones, has spanned several decades. The vaccine contains three vaccine strains, two attenuated influenza A strains and one attenuated influenza B strain; these vaccine strains are genetic ...
Harry Greenberg, George Kemble
openaire   +1 more source

An attenuated vaccine for AIDS?

The Lancet, 1995
One of the few bright prospects in AIDS research is the findings from a study of an attenuated SIV vaccine in monkeys. The vaccine consists of SIV with the nef region deleted (SIVmac239). All 6 monkeys vaccinated with the nef-deleted virus were still healthy and alive 5 years after vaccination while 11 of the 12 rhesus monkeys administered the virulent
openaire   +2 more sources

Why Young Patients With Cancer Refuse the Human Papillomavirus Vaccine

Ca-A Cancer Journal for Clinicians, 2023
Mike Fillon
exaly  

Home - About - Disclaimer - Privacy